Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60 | Journal of Neurology, Neurosurgery & Psychiatry

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

JNNP 100

Authors

Podcasts

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Multiple sclerosis

Original research

Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Foong YC, Merlo D, Gresle M on behalf of MSBASE study group, et al

Comparing ocrelizumab to interferon/glatiramer acetate in people with multiple sclerosis over age 60

Journal of Neurology, Neurosurgery & Psychiatry 2024;95:767-774.